Antineoplastic effects of mammalian target of rapamycine inhibitors

doi:10.5500/wjt.v2.i5.74

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5330)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

484

HTML

4143

Figures (1-4)

476

Tables (1-3)

227

Sum=5330

Oct 24, 2012 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Transplant. Oct 24, 2012; 2(5): 74-83
Published online Oct 24, 2012. doi: 10.5500/wjt.v2.i5.74

Full Size Figure Download Figure

Figure 4 Mammalian target of rapamycin pathway is deregulated by mutations in cancer. PI3K: Phosphoinositide 3-kinase; mTOR: Mammalian target of rapamycin; IGF: Insulin like growth factor; EGF: Epidermal growth factor; VEGF: Vascular endothelial growth factor; ER: Estrogen receptor; TSC: Tuberous sclerosis complex.

Citation: Salvadori M. Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant 2012; 2(5): 74-83
URL: https://www.wjgnet.com/2220-3230/full/v2/i5/74.htm
DOI: https://dx.doi.org/10.5500/wjt.v2.i5.74